PFS
URGN icon

Prospera Financial Services’s UroGen Pharma URGN Stock Holding History

Prospera Financial Services’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-350
Closed -$3K – 2563
2022
Q1 		$3K Buy
+350
New +$2.73K ﹤0.01% 2423

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Prospera Financial Services's URGN Position: Q2 2022 in Review

Prospera Financial Services sold out of UroGen Pharma (URGN) in Q2 2022, closing a stake of 350 shares — an estimated $3K sold.

Prospera Financial Services first reported a position in URGN in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 65 funds tracked by Wall St. Rank hold URGN as of Q2 2022.

  • Prospera Financial Services reported no remaining UroGen Pharma position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 350 UroGen Pharma shares in Q2 2022, an estimated $3K.
  • Prospera Financial Services first reported a position in UroGen Pharma in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's UroGen Pharma position peaked at $3K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.